RAMP 301

{ "short_title": "RAMP 301", "data_mode": "900", "data_mode_number": "000002428", "official_title": "A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "neoadjuvant", "therapielinie_value": "gtThird", "ctgov_number": "NCT06072781", "eudract_number": null, "general_contact_email": "studiensekretariat.gyn@ukdd.de", "general_contact_phone": "+49 351-4584202", "hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger", "description_laie_de": "In dieser Studie werden die Sicherheit und Wirksamkeit von Avutometinib (VS-6766) in Kombination mit Defactinib im Vergleich zu den vom Pr\u00fcfer gew\u00e4hlten Behandlungsmethoden (ICT) bei Patienten mit rezidivierendem LGSOC untersucht, bei denen eine vorherige platinbasierte Therapie eine Progression gezeigt hat.", "description_laie_en": "This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.", "description_expert_de": "Eine randomisierte, offene Phase-3-Studie zur Kombinationstherapie mit Avutometinib plus Defactinib im Vergleich zur Behandlungswahl des Pr\u00fcfarztes bei Patienten mit rezidivierendem niedriggradigem ser\u00f6sem Eierstockkrebs (LGSOC)", "description_expert_en": "A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator\u2019s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 3, "sub_cat_id": 15 }